Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma

Zhenjiang Zhao, Guoguo Jin, Ke Yao, Kangdong Liu, Fangfang Liu, Hanyong Chen, Keke Wang, Dhilli Rao Gorja, Srinivasa Reddy Kanamata Reddy, Ann M. Bode, Zhiping Guo, Zigang Dong

Research output: Contribution to journalArticle

Abstract

Osteosarcoma is the primary human malignant tumor affecting bone. This cancer most frequently arises in children and adolescents, with a second peak in those over the age of 50. Currently, surgery followed by radiotherapy and chemotherapy are the main treatments, but long-term positive effects are very poor. Aurora B kinase is a serine/threonine kinase that is a key regulator of cell cycle and mitosis. Tissue array analysis revealed that Aurora B kinase is overexpressed in osteosarcoma compared with normal bone tissue. We developed a compound, HOI-07 (i.e., (E)-3-((E)-4-(benzo[d] [1,3]dioxol-5-yl)-2-oxobut-3-en-1-ylidene)indolin-2-one), as a specific Aurora B kinase inhibitor and examined its effectiveness against osteosarcoma cell growth in this study. This compound inhibited Aurora B kinase activity in osteosarcoma and induced apoptosis, caused G2-M phase arrest, and attenuated osteosarcoma anchorage-independent cell growth. Moreover, knocking down the expression of Aurora B effectively reduced the sensitivity of osteosarcoma to HOI-07. Results of a xenograft mouse study indicated that HOI-07 treatment effectively suppressed the growth of 143B and KHOS xenografts, without affecting the body weight of mice. The expression of phosphorylated histone H3 (Ser10) was reduced in mice treated with HOI-07. Overall, we identified HOI-07 as a specific Aurora B kinase inhibitor for osteosarcoma treatment and this compound warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1056-1067
Number of pages12
JournalMolecular Carcinogenesis
Volume58
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Aurora Kinase B
Osteosarcoma
Growth
Heterografts
Tissue Array Analysis
Bone and Bones
G2 Phase
Protein-Serine-Threonine Kinases
Mitosis
Cell Division
Histones
3-(4-(benzo(d)(1,3)dioxol-5-yl)-2-oxobut-3-en-1-ylidene)indolin-2-one
Neoplasms
Cell Cycle
Radiotherapy
Therapeutics
Body Weight
Apoptosis
Drug Therapy

Keywords

  • Aurora kinases
  • HOI-07
  • mitosis
  • osteosarcoma
  • targeted therapy

PubMed: MeSH publication types

  • Journal Article

Cite this

Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma. / Zhao, Zhenjiang; Jin, Guoguo; Yao, Ke; Liu, Kangdong; Liu, Fangfang; Chen, Hanyong; Wang, Keke; Gorja, Dhilli Rao; Kanamata Reddy, Srinivasa Reddy; Bode, Ann M.; Guo, Zhiping; Dong, Zigang.

In: Molecular Carcinogenesis, Vol. 58, No. 6, 01.06.2019, p. 1056-1067.

Research output: Contribution to journalArticle

Zhao, Z, Jin, G, Yao, K, Liu, K, Liu, F, Chen, H, Wang, K, Gorja, DR, Kanamata Reddy, SR, Bode, AM, Guo, Z & Dong, Z 2019, 'Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma', Molecular Carcinogenesis, vol. 58, no. 6, pp. 1056-1067. https://doi.org/10.1002/mc.22993
Zhao, Zhenjiang ; Jin, Guoguo ; Yao, Ke ; Liu, Kangdong ; Liu, Fangfang ; Chen, Hanyong ; Wang, Keke ; Gorja, Dhilli Rao ; Kanamata Reddy, Srinivasa Reddy ; Bode, Ann M. ; Guo, Zhiping ; Dong, Zigang. / Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma. In: Molecular Carcinogenesis. 2019 ; Vol. 58, No. 6. pp. 1056-1067.
@article{7e83664b97f2451caf6022c0dd67c6d4,
title = "Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma",
abstract = "Osteosarcoma is the primary human malignant tumor affecting bone. This cancer most frequently arises in children and adolescents, with a second peak in those over the age of 50. Currently, surgery followed by radiotherapy and chemotherapy are the main treatments, but long-term positive effects are very poor. Aurora B kinase is a serine/threonine kinase that is a key regulator of cell cycle and mitosis. Tissue array analysis revealed that Aurora B kinase is overexpressed in osteosarcoma compared with normal bone tissue. We developed a compound, HOI-07 (i.e., (E)-3-((E)-4-(benzo[d] [1,3]dioxol-5-yl)-2-oxobut-3-en-1-ylidene)indolin-2-one), as a specific Aurora B kinase inhibitor and examined its effectiveness against osteosarcoma cell growth in this study. This compound inhibited Aurora B kinase activity in osteosarcoma and induced apoptosis, caused G2-M phase arrest, and attenuated osteosarcoma anchorage-independent cell growth. Moreover, knocking down the expression of Aurora B effectively reduced the sensitivity of osteosarcoma to HOI-07. Results of a xenograft mouse study indicated that HOI-07 treatment effectively suppressed the growth of 143B and KHOS xenografts, without affecting the body weight of mice. The expression of phosphorylated histone H3 (Ser10) was reduced in mice treated with HOI-07. Overall, we identified HOI-07 as a specific Aurora B kinase inhibitor for osteosarcoma treatment and this compound warrants further investigation.",
keywords = "Aurora kinases, HOI-07, mitosis, osteosarcoma, targeted therapy",
author = "Zhenjiang Zhao and Guoguo Jin and Ke Yao and Kangdong Liu and Fangfang Liu and Hanyong Chen and Keke Wang and Gorja, {Dhilli Rao} and {Kanamata Reddy}, {Srinivasa Reddy} and Bode, {Ann M.} and Zhiping Guo and Zigang Dong",
year = "2019",
month = "6",
day = "1",
doi = "10.1002/mc.22993",
language = "English (US)",
volume = "58",
pages = "1056--1067",
journal = "Molecular Carcinogenesis",
issn = "0899-1987",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma

AU - Zhao, Zhenjiang

AU - Jin, Guoguo

AU - Yao, Ke

AU - Liu, Kangdong

AU - Liu, Fangfang

AU - Chen, Hanyong

AU - Wang, Keke

AU - Gorja, Dhilli Rao

AU - Kanamata Reddy, Srinivasa Reddy

AU - Bode, Ann M.

AU - Guo, Zhiping

AU - Dong, Zigang

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Osteosarcoma is the primary human malignant tumor affecting bone. This cancer most frequently arises in children and adolescents, with a second peak in those over the age of 50. Currently, surgery followed by radiotherapy and chemotherapy are the main treatments, but long-term positive effects are very poor. Aurora B kinase is a serine/threonine kinase that is a key regulator of cell cycle and mitosis. Tissue array analysis revealed that Aurora B kinase is overexpressed in osteosarcoma compared with normal bone tissue. We developed a compound, HOI-07 (i.e., (E)-3-((E)-4-(benzo[d] [1,3]dioxol-5-yl)-2-oxobut-3-en-1-ylidene)indolin-2-one), as a specific Aurora B kinase inhibitor and examined its effectiveness against osteosarcoma cell growth in this study. This compound inhibited Aurora B kinase activity in osteosarcoma and induced apoptosis, caused G2-M phase arrest, and attenuated osteosarcoma anchorage-independent cell growth. Moreover, knocking down the expression of Aurora B effectively reduced the sensitivity of osteosarcoma to HOI-07. Results of a xenograft mouse study indicated that HOI-07 treatment effectively suppressed the growth of 143B and KHOS xenografts, without affecting the body weight of mice. The expression of phosphorylated histone H3 (Ser10) was reduced in mice treated with HOI-07. Overall, we identified HOI-07 as a specific Aurora B kinase inhibitor for osteosarcoma treatment and this compound warrants further investigation.

AB - Osteosarcoma is the primary human malignant tumor affecting bone. This cancer most frequently arises in children and adolescents, with a second peak in those over the age of 50. Currently, surgery followed by radiotherapy and chemotherapy are the main treatments, but long-term positive effects are very poor. Aurora B kinase is a serine/threonine kinase that is a key regulator of cell cycle and mitosis. Tissue array analysis revealed that Aurora B kinase is overexpressed in osteosarcoma compared with normal bone tissue. We developed a compound, HOI-07 (i.e., (E)-3-((E)-4-(benzo[d] [1,3]dioxol-5-yl)-2-oxobut-3-en-1-ylidene)indolin-2-one), as a specific Aurora B kinase inhibitor and examined its effectiveness against osteosarcoma cell growth in this study. This compound inhibited Aurora B kinase activity in osteosarcoma and induced apoptosis, caused G2-M phase arrest, and attenuated osteosarcoma anchorage-independent cell growth. Moreover, knocking down the expression of Aurora B effectively reduced the sensitivity of osteosarcoma to HOI-07. Results of a xenograft mouse study indicated that HOI-07 treatment effectively suppressed the growth of 143B and KHOS xenografts, without affecting the body weight of mice. The expression of phosphorylated histone H3 (Ser10) was reduced in mice treated with HOI-07. Overall, we identified HOI-07 as a specific Aurora B kinase inhibitor for osteosarcoma treatment and this compound warrants further investigation.

KW - Aurora kinases

KW - HOI-07

KW - mitosis

KW - osteosarcoma

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85062340341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062340341&partnerID=8YFLogxK

U2 - 10.1002/mc.22993

DO - 10.1002/mc.22993

M3 - Article

C2 - 30790360

AN - SCOPUS:85062340341

VL - 58

SP - 1056

EP - 1067

JO - Molecular Carcinogenesis

JF - Molecular Carcinogenesis

SN - 0899-1987

IS - 6

ER -